Gilead (GILD) Officer RSU Grant and Share Disposition Reported

Rhea-AI Filing Summary

Gilead Sciences (GILD) Form 4 filed for Johanna Mercier, Chief Commercial Officer. The filing reports on 09/10/2025 the grant of 3,844 restricted stock units (RSUs), each representing the right to one share, and the sale/disposition of 1,819 shares at $115.25 per share. After these transactions Mercier beneficially owned 116,193 shares on a direct basis. The RSUs carry a four-year vesting schedule with 25% vesting at the first anniversary and the remainder vesting quarterly at 6.25% until fully vested. The Form 4 is signed by an authorized power of attorney on behalf of the reporting person.

Positive

• 3,844 restricted stock units granted, which supports executive retention through a standard four‑year vesting schedule
• Clear vesting schedule disclosed: 25% after one year and 6.25% quarterly thereafter, providing transparency on timing of potential share issuance

Negative

• Disposition of 1,819 shares at $115.25 reduced direct beneficial ownership to 116,193 shares

Insights

Corporate Governance Expert

TL;DR: Routine executive equity activity showing a standard RSU grant and an unrelated share disposition.

The Form 4 documents a standard equity compensation action: a grant of 3,844 RSUs with a four-year vesting schedule and a contemporaneous disposition of 1,819 shares at $115.25. This pattern is consistent with regular compensation and portfolio management by an officer rather than a material corporate event. The filing is informational for shareholders tracking insider holdings and executive alignment with shareholder interests.

Compensation Analyst

TL;DR: Compensation update confirming time‑based retention RSUs and a small sale at a disclosed price.

The grant specifies time‑based RSUs that vest 25% after one year and 6.25% quarterly thereafter, a customary schedule for retention. The disposition of 1,819 shares at $115.25 is recorded separately and reduces direct beneficial ownership to 116,193 shares. There is no disclosure of performance conditions or extraordinary terms in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mercier Johanna

(Last) (First) (Middle)

GILEAD SCIENCES, INC.

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2025		M		3,844	A	(1)	118,012	D
Common Stock	09/10/2025		F		1,819	D	$115.25	116,193	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	09/10/2025		M			3,844	(2)	(2)	Common Stock	3,844	(1)	31,516	D

Explanation of Responses:

1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

2. The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Remarks:

	/s/ Edward S. Son by Power of Attorney for Johanna Mercier	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions does the GILD Form 4 for Johanna Mercier report?

The Form 4 reports a grant of 3,844 restricted stock units (RSUs) and a disposition of 1,819 shares sold at $115.25 per share on 09/10/2025.

How many shares does Johanna Mercier beneficially own after the reported transactions?

After the transactions Mercier beneficially owned 116,193 shares on a direct basis according to the Form 4.

What are the vesting terms of the RSUs granted to the reporting person?

Each RSU vests over four years with 25% vesting on the first anniversary and the remaining balance vesting at 6.25% quarterly until fully vested.

Does the Form 4 indicate any performance conditions tied to the RSUs?

No. The filing states the awards are restricted stock units with a time‑based four‑year vesting schedule and does not disclose performance conditions.

Who signed the Form 4 filing for Johanna Mercier?

The Form 4 was signed on behalf of Johanna Mercier by Edward S. Son by Power of Attorney on 09/11/2025.